ストックスクリーナーアプリを入手
31.70
4.91%
1.53
前日終値:
$30.17
開ける：
$31.23
24時間の取引高:
254.68K
Relative Volume:
0.85
時価総額：
$904.01M
収益：
-
当期純損益:
$-69.47M
株価収益率:
-5.6634
EPS:
-5.5973
ネットキャッシュフロー:
$-73.92M
1週間 パフォーマンス:
+6.32%
1か月 パフォーマンス:
+0.54%
6か月 パフォーマンス:
+25.20%
1年 パフォーマンス:
+36.48%
1日の値動き範囲:
$30.55
$32.25
1週間の範囲:
$27.79
$32.25
52週間の値動き範囲:
$16.54
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
名前
Lenz Therapeutics Inc
セクター
電話
858-925-7000
住所
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
LENZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
31.70 | 869.35M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
382.32 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.41 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.62 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.49 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.87 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-14 | 再開されました | Piper Sandler | Overweight |
| 2025-03-18 | 開始されました | TD Cowen | Buy |
| 2024-09-27 | 開始されました | Raymond James | Outperform |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-15 | 開始されました | Leerink Partners | Outperform |
| 2024-04-15 | 開始されました | William Blair | Outperform |
| 2024-04-10 | 開始されました | Citigroup | Buy |
| 2024-03-27 | 開始されました | Piper Sandler | Overweight |
| 2023-02-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-02-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | ダウングレード | Cowen | Outperform → Market Perform |
| 2023-01-25 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-01-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-01-06 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-14 | 開始されました | BTIG Research | Buy |
| 2022-03-22 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | 開始されました | Morgan Stanley | Overweight |
| 2021-07-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Lenz Therapeutics Inc (LENZ) 最新ニュース
A Quick Look at Today's Ratings for LENZ Therapeutics(LENZ.US), With a Forecast Between $40 to $60 - 富途牛牛
Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye Drops - TipRanks
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright By Investing.com - Investing.com South Africa
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright - Investing.com Australia
What are LENZ Therapeutics Inc. company’s key revenue driversMaximize gains with timely market signals - Jammu Links News
How many analysts rate LENZ Therapeutics Inc. as a “Buy”Phenomenal wealth increase - Jammu Links News
What analysts say about LENZ Therapeutics Inc. stockRecord-setting profit potential - Jammu Links News
When is LENZ Therapeutics Inc. stock expected to show significant growthGet real-time alerts on high-potential stocks - Jammu Links News
What are the latest earnings results for LENZ Therapeutics Inc.Free Expert Stock Watchlist - Jammu Links News
Is LENZ Therapeutics Inc. a good long term investmentStrong return on assets - jammulinksnews.com
LENZ Therapeutics Inc. Stock Analysis and ForecastMaximize returns with expert trading insights - Jammu Links News
What is the dividend policy of LENZ Therapeutics Inc. stockHigh-octane investment gains - Jammu Links News
What catalysts could drive LENZ Therapeutics Inc. stock higher in 2025Achieve superior returns with professional insights - Jammu Links News
What is the risk reward ratio of investing in LENZ Therapeutics Inc. stockConsistently outstanding ROI - jammulinksnews.com
How volatile is LENZ Therapeutics Inc. stock compared to the marketLightning-fast growth - Jammu Links News
Why is LENZ Therapeutics Inc. stock attracting strong analyst attentionAchieve consistent returns with proven methods - Jammu Links News
Volume spikes in LENZ Therapeutics Inc. stock – what they meanFree Real Time Alerts Based on AI Prediction - Newser
LENZ Therapeutics (NASDAQ:LENZ) Sees Unusually-High Trading Volume After Analyst Upgrade - Defense World
Is it time to cut losses on LENZ Therapeutics Inc.Free Step-by-Step Stock Investment Guide - Newser
Using data models to predict LENZ Therapeutics Inc. stock movementTen-Year Sector Performance and Summary Analysis - Newser
William Blair Expects Weaker Earnings for LENZ Therapeutics - Defense World
Published on: 2025-08-01 19:39:34 - Newser
Citi maintains Buy rating on LENZ Therapeutics, raises PT to $52 from $49. - AInvest
LENZ Therapeutics announces FDA Approval of VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia - Eyes On Eyecare
FDA approves LENZ Therapeutics' VIZZ for presbyopia - Eyes On Eyecare
Eyes on the prize: FDA approves Lenz’s drops for presbyopia - BioWorld MedTech
LENZ Therapeutics' Eye Drop Scores First FDA Approval… - inkl
LENZ Therapeutics gets FDA nod for presbyopia eye drop (LENZ) - Seeking Alpha
LENZ Therapeutics Stock Soars 12.5% on FDA Approval of VIZZ - AInvest
Analysts Are Bullish on These Healthcare Stocks: LENZ Therapeutics (LENZ), GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
Applying big data sentiment scoring on LENZ Therapeutics Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser
LENZ Therapeutics Announces FDA Approval of VIZZ for Treatment of Presbyopia - VisionMonday.com
Has LENZ Therapeutics Inc. found a price floorFree Triple Digit Return Stock Predictions - Newser
Citigroup maintains Buy rating on LENZ Therapeutics, raises PT to $49. - AInvest
Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia - Conexiant
Lenz Therapeutics stock rises after FDA approves presbyopia eye drops - Investing.com Australia
Lenz Therapeutics stock rises after FDA approves presbyopia eye drops By Investing.com - Investing.com Canada
LENZ Therapeutics Gains FDA Approval for VIZZ Eye Drop - MSN
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia - The Manila Times
FDA Approval: Revolutionary 10-Hour Eye Drops Promise Freedom from Reading Glasses - Stock Titan
Lenz (LENZ) Q2 Revenue Jumps 604% - The Motley Fool
Lenz Therapeutics Prepares for LNZ100 Launch - TipRanks
Is a relief rally coming for LENZ Therapeutics Inc. holdersFree AI Powered High Return Stock Calls - Newser
FY2025 EPS Estimate for LENZ Therapeutics Lifted by Analyst - Defense World
LENZ Therapeutics gains on NDA submission in China for presbyopia drug LNZ100 - MSN
LENZ Therapeutics shares climb as FDA review of presbyopia treatment stays on schedule - MSN
Biotech Stocks Under FDA Review in August 2025: LENZ Therapeutics and PharmaTher Holdings - AInvest
LENZ Therapeutics shares surge as FDA review of presbyopia drug on track - Investing.com Australia
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss - Yahoo Finance
How Efficient Is LENZ Therapeutics Inc. at Controlling Operating CostsStrong Buy With Technical Confidence Supported - metal.it
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Lenz Therapeutics Inc (LENZ) 財務データ
収益
当期純利益
現金流量
EPS
Lenz Therapeutics Inc (LENZ) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Jun 27 '25 |
Sale |
30.46 |
200,000 |
6,093,000 |
1,767,275 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.25 |
133,924 |
4,051,201 |
1,967,275 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.35 |
100,877 |
3,061,617 |
1,047,912 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 18 '25 |
Sale |
29.95 |
100,000 |
2,995,000 |
1,148,789 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 10 '25 |
Sale |
29.00 |
350,000 |
10,150,000 |
1,248,789 |
| Olsson Shawn | Chief Commercial Officer |
Apr 09 '25 |
Option Exercise |
2.08 |
1,400 |
2,912 |
4,733 |
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 07 '25 |
Option Exercise |
1.04 |
4,200 |
4,368 |
49,200 |
| Olsson Shawn | Chief Commercial Officer |
Dec 16 '24 |
Option Exercise |
2.08 |
3,333 |
6,933 |
3,333 |
0.08%
1.75%
大文字化:
|
ボリューム (24 時間):